Stockscreener 앱 받기
551.50
0.62%
-3.44
시간 외 거래:
547.30
-4.20
-0.76%
전일 마감가:
$554.94
열려 있는:
$554.09
하루 거래량:
1.28M
Relative Volume:
2.11
시가총액:
$43.50B
수익:
$4.45B
순이익/손실:
$1.10B
주가수익비율:
40.58
EPS:
13.591
순현금흐름:
$1.06B
1주 성능:
-1.88%
1개월 성능:
-1.02%
6개월 성능:
-19.90%
1년 성능:
+4.49%
1일 변동 폭
$547.19
$561.15
1주일 범위
$538.44
$570.84
52주 변동 폭
$506.91
$769.98
아이덱스 래버러토리스 Stock (IDXX) Company Profile
명칭
Idexx Laboratories Inc
전화
(207) 556-0300
주소
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, A, NTRA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
아이덱스 래버러토리스 Stock (IDXX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Citigroup | Neutral |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-31 | 업그레이드 | Stifel | Hold → Buy |
| 2025-10-01 | 개시 | UBS | Neutral |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-01 | 개시 | Jefferies | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | BTIG Research | Buy |
| 2024-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | 개시 | Exane BNP Paribas | Outperform |
| 2023-12-04 | 업그레이드 | Cleveland Research | Neutral → Buy |
| 2023-08-02 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-07-12 | 개시 | Piper Sandler | Overweight |
| 2022-05-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-08 | 개시 | Atlantic Equities | Overweight |
| 2021-11-18 | 개시 | Morgan Stanley | Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-17 | 개시 | Barclays | Overweight |
| 2019-09-09 | 개시 | Goldman | Neutral |
| 2019-05-23 | 개시 | Guggenheim | Buy |
| 2018-11-02 | 재확인 | BofA/Merrill | Buy |
| 2018-05-07 | 재확인 | Stifel | Buy |
| 2018-01-16 | 개시 | Piper Jaffray | Overweight |
| 2017-08-23 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | 업그레이드 | CL King | Neutral → Buy |
| 2017-02-03 | 다운그레이드 | Feltl & Co. | Hold → Sell |
| 2016-09-29 | 재개 | BofA/Merrill | Neutral |
| 2016-08-16 | 재확인 | Stifel | Buy |
| 2016-08-03 | 업그레이드 | Northcoast | Sell → Neutral |
| 2016-07-20 | 재확인 | Canaccord Genuity | Buy |
| 2016-04-19 | 재확인 | Canaccord Genuity | Buy |
| 2016-04-01 | 개시 | CL King | Neutral |
| 2016-03-21 | 재확인 | Stifel | Buy |
| 2016-02-04 | 개시 | Credit Suisse | Outperform |
| 2015-10-29 | 재확인 | Stifel | Buy |
| 2015-08-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | 재확인 | Stifel | Buy |
| 2015-07-23 | 재확인 | Canaccord Genuity | Buy |
모두보기
아이덱스 래버러토리스 주식(IDXX)의 최신 뉴스
IDEXX Laboratories opens the week with earnings focus, shares steady - Ad-hoc-news.de
Is IDEXX Laboratories stock underperforming the Nasdaq? - MSN
IDEXX Laboratories, Inc. Actuals & Estimates (VIE:IDXX) - TradingView
IDEXX Laboratories sets the pace with raised 2026 guidance, analysts back the stock - Ad-hoc-news.de
Enterprise value to EBITDA forward of IDEXX Laboratories, Inc. – DUS:IX1 - TradingView
Why IDEXX Laboratories Stock Looks Undervalued After Raising Its 2026 EPS Outlook to $15 - TIKR.com
IDEXX Laboratories Inc (IDXX) Institutional Confidence - TradingKey
Price to book forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
Enterprise value to revenue forward of IDEXX Laboratories, Inc. – NASDAQ:IDXX - TradingView
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX Laboratories analyst consensus stays firm, shares trade below recent high - Ad-hoc-news.de
IDEXX Laboratories Inc (IDXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
SNAP 4Dx Plus Test from IDEXX Laboratoriesquick tick-borne screening in minutes - Ad-hoc-news.de
IDEXX Laboratories Inc. stock underperforms Monday when compared to competitors - MarketWatch
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999. - marketscreener.com
A Small Upgrade Could Have a Big Impact for IDEXX Customers - Insider Monkey
IDEXX Laboratories StockSaturday deep dive into the long-term business model - Ad-hoc-news.de
New diagnostic test for kidney injury - DVM360
IDEXX Laboratories Sharesanalyst consensus stays cautious - Ad-hoc-news.de
IDEXX Laboratories Stock Is Down 16% in 2026: Does the Q1 Beat Make It a Buy at $562? - TIKR.com
Why IDEXX Neo practice software wants to disappear into the background - AD HOC NEWS
IDEXX Laboratories Inc (IDXX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
IDEXX Laboratories Inc (IDXX) Valuation: PE, PB & Fair Value Analysis - TradingKey
IDEXX Laboratories Inc (IDXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IDEXX Laboratories Inc (IDXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
IDEXX Laboratories Inc (IDXX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IDEXX Laboratories Inc (IDXX) Stock Down 4.7% -- Now Undervalued? GF Score: 96/100 - GuruFocus
IDEXX Laboratories Inc (IDXX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories Inc (IDXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IDEXX Laboratories Inc. stock rises Monday, still underperforms market - MarketWatch
IDEXX Laboratories Inc Stock (US45167R1041): valuation metrics in focus for S&P 500 diagnostics name - Ad-hoc-news.de
IDEXX Laboratories Stock (US45168D1046): Technical signal after 38-day moving average crossover - AD HOC NEWS
IDEXX Laboratories Stock (US45168D1046): Valuation and fundamentals in focus for S&P 500 pet-health - AD HOC NEWS
IDEXX Laboratories stock (US45168D1046): Double-digit jump after strong earnings and Nasdaq 100 outp - Ad-hoc-news.de
IDEXX Laboratories Stock’s 63% Gross Margin Story: Here’s What the Numbers Say About a $909 Target - TIKR.com
Is It Too Late to Buy IDEXX Laboratories Inc (IDXX) After 3.2% R - GuruFocus
Is IDEXX Laboratories Stock Underperforming the Nasdaq? - Barchart.com
Idexx appears to have plate-reading cameras monitoring Maine properties - The Portland Press Herald
BARON GROWTH FUND's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
Is Wall Street bullish or bearish on IDEXX Laboratories stock? - MSN
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: A 26% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
IDEXX Laboratories touts AI push, inVue Dx momentum at Stifel conference - MSN
Idexx (IDXX) Down 3.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
IDEXX Parasite Test Expansion Links Zoonotic Risk And Valuation Debate - Yahoo Finance
IDEXX (IDXX) EVP Fennell reports RSU vesting and tax share withholding - Stock Titan
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
아이덱스 래버러토리스 (IDXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.37%
0.66%
자본화:
|
볼륨(24시간):